Greatland Gold plc (GRLGF)

Ligand Pharmaceuticals Income Statement

Financials in millions GBP. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Selling, General & Admin	8.39	5.68	5.72	5.22	1.85	1.7
Other Operating Expenses	0.93	0.71	0.09	0.18	-	-
Operating Expenses	16.48	13.88	18.98	8.62	5.32	5.2
Operating Income	-13.7	-13.88	-18.98	-8.62	-5.32	-5.2
Interest Expense	-0.01	-0.01	-0.01	-0.02	-0.02	-0.02
Interest & Investment Income	2.29	0.82	1.23	0	0	0.02
Currency Exchange Gain (Loss)	6.27	-0.13	-1.67	-2.74	-0.19	-
Other Non Operating Income (Expenses)	-0.14	-0.15	-1.69	-0	0.01	-
EBT Excluding Unusual Items	-5.29	-13.35	-21.12	-11.37	-5.52	-5.2
Merger & Restructuring Charges	-8.27	-1.52	-	-	-	-
Other Unusual Items	-	-	-	-	-	0.06
Pretax Income	-13.57	-14.87	-21.12	-11.37	-5.52	-5.14
Net Income	8.63	-14.87	-21.12	-11.37	-5.52	-5.14
Net Income to Common	8.63	-14.87	-21.12	-11.37	-5.52	-5.14
Shares Outstanding (Basic)	6,616	5,085	4,850	4,016	3,873	3,593
Shares Outstanding (Diluted)	6,683	5,085	4,850	4,016	3,873	3,593
Shares Change (YoY)	31.79%	4.84%	20.75%	3.71%	7.77%	10.47%
EPS (Basic)	0.00	-0.00	-0.00	-0.00	-0.00	-0.00
EPS (Diluted)	0.00	-0.00	-0.00	-0.00	-0.00	-0.00
Free Cash Flow	-26.49	-24.6	-25.99	-26.5	-12.05	-4.66
Free Cash Flow Per Share	-0.00	-0.01	-0.01	-0.01	-0.00	-0.00
EBITDA	-11.08	-13.85	-18.96	-8.58	-5.14	-5.09
D&A For EBITDA	2.62	0.03	0.03	0.04	0.18	0.11
EBIT	-13.7	-13.88	-18.98	-8.62	-5.32	-5.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.